摘要
目的评价新型羟自由基消除剂—依达拉奉对高血压脑出血后继发性脑损伤的治疗效果。方法对60例重症高血压脑出血微创术后患者随机分为治疗组30例和对照组30例,治疗组给予依达拉奉注射液30m g2/d,共14d,同时给予抗生素、赖氨酸及对症治疗;对照组除不用依达拉奉外,余同治疗组。采用G O S及日常生活能力量表评分,比较两组的近期(21d)和远期(3个月)疗效。结果治疗组近期优良率(68.1%)和远期治愈及良好患者比率(76.9%)明显高于对照组(40.3%,45.5%),差异有显著性(P<0.05);治疗组的近期死亡率(6.7%)明显低于对照组(20%),差异有显著性(P<0.01);而治疗组无明显不良反应。结论依达拉奉对高血压脑出血继发性脑损伤的治疗是安全有效的。
Objective To evaluate the curative effect of Edaravone, a new-type hydroxy radical remover, on curing brain damage secondary to hypertension intracerebral hemorrhage. Methods 60 serious cases of hypertension intracerebral hemorrhage were divided randomly after minimally invasive surgery into treatment group （30 cases） and control group （30 cases）. The patients in treatment group were injected intravenously with 30 mg 2/d for 14 days. Meantime, antibiotics, lysine and expectant treatment were carried on. The same treatment except Edaravone injection was implemented in the control group. The curative effect of short-term （21 d） and long-term （3 months） was compared between the two groups in way of GOS and activities of daily living （ADL） scale, Results The short-term“good” rate （68.1%） and the long-term “good and above”（76.9% ） rate of the treatment group are clearly higher than the control group （40.3%, 45.5%）, with a significant difference （P〈0.05）. The short-term death rate of the treatment group （6.7%） is obviously lower （P〈0.01） than that the control group （20%）. No obvious bad reaction occurred in the treatment group. Conclusion Edaravone is safe and effective in the treatment of brain damage secondary to hypertension intracerebral hemorrhage.
出处
《中华神经医学杂志》
CAS
CSCD
2005年第8期837-838,共2页
Chinese Journal of Neuromedicine
关键词
依达拉奉
脑出血
继发性脑损伤
Edaravone
Intracerebral hemorrhage
Secondary brain damage
